{"schema_version":"secwatch.filing_event.v1","accession":"0001739410-24-000040","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2024-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.834532+00:00","generated_at":"2026-06-04T00:28:46.511842+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rallybio announces J&J collaboration with $0.5M upfront and $6.6M equity for FNAIT","bullets":["Collaboration with J&J: Rallybio receives $0.5M upfront, up to $3.7M milestones for FNAIT data sharing and awareness.","J&J affiliate JJDC invests $6.6M via purchase of 3.6M shares in private placement at ~$1.82/share.","Rallybio's RLYB212 (preventative for non-alloimmunized) and J&J's nipocalimab (for alloimmunized) target FNAIT; Phase 2 for RLYB212 expected H2 2024.","JJDC locked up from selling shares for 180 days; collaboration agreement expires April 9, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001739410-24-000040","json":"https://secwatch.observer/filing/0001739410-24-000040.json","markdown":"https://secwatch.observer/filing/0001739410-24-000040.md","text":"https://secwatch.observer/filing/0001739410-24-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000040/0001739410-24-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000040/rlyb-20240409.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:28:46.511842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"150bc7a13097ea0ddbea78c2335ec5018af85f3e","claim":"Rallybio Corp entered into Collaboration Agreement with Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. valued at $0.5 million (effective 2024-04-09).","evidence_excerpt":"On April 9, 2024, Rallybio Corporation (the “Company”), through its subsidiary Rallybio IPA, LLC, entered into a collaboration agreement (the “Collaboration Agreement”) with Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. (“J&J”),","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000040/0001739410-24-000040-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Johnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc."},{"label":"Value","value":"$0.5 million"},{"label":"Effective","value":"2024-04-09"}],"fact_type":"material_agreement"},{"claim_id":"f589650dc23eabdf143ff776cb5778350cb58903","claim":"Rallybio Corp entered into Securities Purchase Agreement with Johnson & Johnson Innovation – JJDC, Inc. valued at approximately $6.6 million (effective 2024-04-10).","evidence_excerpt":"On April 10, 2024, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Johnson & Johnson Innovation – JJDC, Inc., a Delaware corporation (the “Purchaser”), pursuant to which the Company sold to the Purchaser, in an unregistered offering (the “Offering”), shares of common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000040/0001739410-24-000040-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Johnson & Johnson Innovation – JJDC, Inc."},{"label":"Value","value":"approximately $6.6 million"},{"label":"Effective","value":"2024-04-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}